Clinical Trial Detail

NCT ID NCT02775903
Title An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celgene Corporation
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Azacitidine

Azacitidine + Durvalumab

Age Groups: adult senior

No variant requirements are available.